Provided By GlobeNewswire
Last update: May 15, 2025
Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2
First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3
Read more at globenewswire.comNYSE:TFX (7/18/2025, 3:55:05 PM)
111.01
-2.58 (-2.27%)
Find more stocks in the Stock Screener